IMRN (Immuron) רווח למניה בארבעת הרבעונים האחרונים

Immuron Limited is developing Travelan hyperimmune products in collaboration with the US Army. The 12-month YoY EPS trend links these contracts to a dependence on tourism demand and pharmacy sales. The 42.80 metric reflects current profit dynamics, while the completion of regulatory reports for gastrointestinal antibodies determines the company's future potential.

This indicator measures the percentage change in net earnings per share over the last twelve months relative to the same period last year, reflecting the business's capitalization rate. By analyzing the year-over-year EPS growth dynamics over a rolling period, the investor compares the market value of Immuron Limited (IMRN) with actual returns, which in this case are supported by stable sales of over-the-counter gastrointestinal drugs.